Sun Pharma’s subsidiary has launched Drizalma Sprinkle in the US. It is the first and only USFDA-approved sprinkle formulation of Drizalma Sprinkle, which is delayed-release duloxetine capsules used in treatment of patients suffering from neuro-psychiatric and/or pain disorder accompanied with difficulty in swallowing.
Sprinkle formulations are drug-containing pellets or granules, which can be mixed with soft food or other contents before administration, thus providing a flexibility and convenience of dosage administration to patients with dysphagia. Drizalma Sprinkle which is a serotonin and norepinephrine reuptake inhibitor (SNRI) is indicated for treatment of major depressive disorder (MDD) in adults, generalized anxiety disorder (GAD) in adults and also in pediatric patients, diabetic peripheral neuropathic pain (DPNP) in adults and chronic musculoskeletal pain in adults.
The formulation of duloxetine can be swallowed whole, administered via nasogastric tube, or sprinkled on applesauce. The drug is available in four dosage strengths as 20mg, 30mg, 40mg, and 60mg. Apart from Drizalma Sprinkle, Sun Pharma has launched Ezallor Sprinkle (Rosuvastatin) and Kapspargo Sprinkle (metoprolol succinate) extended-release capsules as part of its sprinkle formulations drugs portfolio, keeping in focus the treatment needs of individuals in long-term care.